

Supporting information

**Solvent controlled amidation of acid chlorides at room temperature:
New route to access aromatic primary amides and imides amenable
for late-stage functionalization**

Chandrasekaran Sivaraj and Thirumanavelan Gandhi*

‡ Department of Chemistry, School of Advanced Sciences,
Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
E-mail: velan.g@vit.ac.in


Table of Contents

Sl. No	Title	Page number
1.	General Information	S2
2.	General Synthesis Procedure	S2-S3
3.	Characterization Data	S4-S14
4.	References	S15
5.	^1H & ^{13}C NMR Spectra	S16-S60

1. General Information


All the reaction were carried out in room temperature. All chemicals were purchased from Sigma-Aldrich, Avra, TCI, these were used without further purifications. Proton nuclear magnetic resonance (¹H-NMR) spectra were recorded on a Bruker BBFO (400 MHz) spectrometer. Chemical shifts were recorded in parts per million (ppm, δ) relative to Tetramethylsilane (δ 0.00) or chloroform (δ = 7.19, singlet). Carbon nuclear magnetic resonance (¹³C-NMR) spectra were recorded on a Bruker BBFO (101 MHz) spectrometer. Analytical thin-layer chromatography (TLC) was carried out on Merck 60 F254 pre-coated silica gel plate (0.2 mm thickness). For Column chromatography 100-200 mesh silica gel used.

2.0 General procedure for the synthesis of primary amides




To a mixture of acid chlorides **1** (100 mg, 1 equiv) and lithium bis(trimethylsilyl)amide (LiHMDS in THF) (2.5 equiv) in a reaction tube with a magnetic stirring bar was added DCE (3 mL) and stirred at room temperature. The reaction mixture was stirred for 5 min at room temperature. After completion of reaction through TLC. Reaction mixture was workup with 1 M HCl solution, extracted with ethyl acetate and concentrated through in vacuo. The crude reaction mixture was purified by column chromatography using Ethyl Acetate-Hexane (50%) to give desired product **2**.

2.1 General procedure for the synthesis of symmetrical imides




To a mixture of acid chlorides **1** (100 mg, 1 equiv) and lithium bis(trimethylsilyl)amide (LiHMDS in THF) (2.5 equiv) in a reaction tube with a magnetic stirring bar was added 1,4-dioxane and stirred at room temperature. The reaction mixture was stirred for 5 min at room temperature. After completion of reaction through TLC. Reaction mixture was workup with 1 M HCl solution, extracted with ethyl acetate and concentrated through in vacuo. The crude reaction mixture was purified by column chromatography using Ethyl Acetate-Hexane (25%) to give desired product **3**.

2.2 General procedure for the synthesis of unsymmetrical imides



To a mixture of acid chlorides **1** (100 mg, 1 equiv), aryl amides **2** (1.1 equiv) and lithium bis(trimethylsilyl)amide (LiHMDS in THF) (2.5 equiv) in a reaction tube with a magnetic stirring bar was added 1,4-dioxane and stirred at room temperature. The reaction mixture was stirred for 5 min at room temperature. After completion of reaction through TLC. Reaction mixture was workup with 1 M HCl solution, extracted with ethyl acetate and concentrated through in vacuo. The crude reaction mixture was purified by column chromatography using Ethyl Acetate-Hexane (24%) to give desired product **4a**.

2.3 General procedure with aliphatic acid chlorides











R= acetyl chloride, Propionyl chloride, cyclohexanecarbonyl chloride, cyclopentanecarbonyl chloride, 2-cyclohexylacetyl chloride




To a mixture of acid chlorides **1** (100 mg, 1 equiv) and lithium bis(trimethylsilyl)amide (LiHMDS in THF) (2.5 equiv) in a reaction tube with a magnetic stirring bar was added DCE (3 mL)/Dioxane (3mL) and stirred at room temperature. The reaction mixture was stirred for 5 min at room temperature. The reaction did not proceed.





3. Characterization Data:




	Benzamide 2a: ¹ white solid, (69 mg, 80%); Mp: 127–129 °C; ¹ H NMR (400 MHz, CDCl ₃): δ 7.75 (d, <i>J</i> = 7.2 Hz, 2H), 7.45 (t, <i>J</i> = 7.4 Hz, 1H), 7.37 (t, <i>J</i> = 7.5 Hz, 2H), 6.25 (s, 2H). ¹³ C NMR (101 MHz, CDCl ₃): δ 169.8, 133.4, 132.0, 128.6, 127.4.
	4-methylbenzamide 2b: ¹ white solid, (74 mg, 75%); Mp: 156–157 °C; ¹ H NMR (400 MHz, CDCl ₃): δ 7.64 (d, <i>J</i> = 8.2 Hz, 2H), 7.18 (d, <i>J</i> = 8.0 Hz, 2H), 6.02 (s, 1H), 5.89 (s, 1H), 2.33 (s, 3H). ¹³ C NMR (101 MHz, CDCl ₃): δ 169.5, 142.6, 130.5, 129.3, 127.4, 21.5.
	4-methoxybenzamide 2c: ¹ white solid, (64 mg, 73%); Mp: 163–165 °C; ¹ H NMR (400 MHz, CDCl ₃): δ 7.71 (d, <i>J</i> = 8.9 Hz, 2H), 6.87 (d, <i>J</i> = 8.9 Hz, 2H), 5.81 (s, 2H), 3.79 (s, 3H). ¹³ C NMR (101 MHz, CDCl ₃): δ 168.8, 162.6, 129.3, 125.5, 113.8, 55.5.
	4-fluorobenzamide 2d: ¹ white solid, 73 mg, 83%); Mp: 137–139 °C; ¹ H NMR (400 MHz, CDCl ₃): δ 7.77 (dd, <i>J</i> = 8.6, 5.3 Hz, 2H), 7.06 (t, <i>J</i> = 8.5 Hz, 2H), 5.94 (s, 2H). ¹³ C NMR (101 MHz, CDCl ₃): δ 168.2, 165.08 (d, <i>J</i> = 252.7 Hz), 129.8 (d, <i>J</i> = 9.1 Hz), 115.73 (d, <i>J</i> = 22.0 Hz)





	¹⁹ F NMR (377 MHz, CDCl ₃): δ -107.22 -- 107.29 (m).
	4-chlorobenzamide 2e: ¹ white solid, (77 mg, 86%); Mp: 179–180 °C; ¹ H NMR (400 MHz, DMSO): δ 8.05 (s, 1H), 7.89 (d, <i>J</i> = 8.6 Hz, 2H), 7.53 (d, <i>J</i> = 8.5 Hz, 2H), 7.45 (s, 1H). ¹³ C NMR (101 MHz, DMSO): δ 167.3, 136.5, 133.5, 129.9, 128.8.
	3-methoxybenzamide 2f: ¹ white solid, (63 mg, 72%); Mp: 120–121 °C; ¹ H NMR (400 MHz, CDCl ₃): δ 7.33 (s, 1H), 7.30–7.26 (m, 2H), 7.01 – 6.99 (m, 1H), 6.08 (s, 1H), 5.93 (s, 1H), 3.78 (s, 3H). ¹³ C NMR (101 MHz, CDCl ₃): δ 169.4, 159.9, 134.7, 129.6, 119.2, 118.3, 112.6, 55.5.
	3-fluorobenzamide 2g: ¹ white solid, (70 mg, 80%); Mp: 128–130 °C; ¹ H NMR (400 MHz, CDCl ₃): δ 7.56 (t, <i>J</i> = 9.8 Hz, 2H), 7.42 (d, <i>J</i> = 7.3 Hz, 1H), 7.23 (d, <i>J</i> = 9.6 Hz, 1H), 6.10 (s, 2H). ¹³ C NMR (101 MHz, CDCl ₃): δ 168.2 (d, <i>J</i> = 2.4 Hz), 162.7 (d, <i>J</i> = 247.9 Hz), 135.5 (d, <i>J</i> = 6.9 Hz), 130.3 (d, <i>J</i> = 7.9 Hz), 122.8 (d, <i>J</i> = 3.1 Hz), 119.11 (d, <i>J</i> = 21.3 Hz), 114.76 (d, <i>J</i> = 23.0 Hz). ¹⁹ F NMR (377 MHz, CDCl ₃): δ -111.63 -- 111.65 (m).
	1-naphthamide 2h: ¹ white solid, (68 mg, 76%); Mp: 198–200 °C; ¹ H NMR (400 MHz, CDCl ₃): δ 8.36 (d, <i>J</i> = 8.4 Hz, 1H), 7.88 (d, <i>J</i> = 8.3 Hz, 1H), 7.82 (d, <i>J</i> = 7.6 Hz, 1H), 7.64 (dd, <i>J</i> = 7.1, 1.1 Hz, 1H), 7.52 (dd, <i>J</i> = 8.5, 6.9, 1.6 Hz, 1H), 7.49 – 7.45 (m, 1H), 7.42 (dd, <i>J</i> = 8.2, 7.1 Hz, 1H), 5.93




	(s, 2H). ^{13}C NMR (101 MHz, CDCl_3): δ 171.5, 133.8, 133.1, 131.2, 130.1, 128.4, 127.3, 126.5, 125.4, 125.4, 124.6.
	2-naphthamide 2i: ¹ White solid, (69 mg, 77%); Mp: 191–192 °C; ^1H NMR (400 MHz, DMSO): δ 8.55 (s, 1H), 8.20 (s, 1H), 8.07 – 8.02 (m, 4H), 7.68 – 7.62 (m, 2H), 7.54 (s, 1H). ^{13}C NMR (101 MHz, DMSO): δ 168.4, 134.6, 132.6, 132.1, 129.3, 128.3, 128.2, 128.1, 128.0, 127.1, 124.9.
	Furan-2-carboxamide 2j: ¹ White solid, (62 mg, 73%); Mp: 142–144 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.41 (s, 1H), 7.10 (s, 1H), 6.46 (s, 1H), 6.23 (s, 1H), 5.78 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3): δ 160.1, 147.4, 144.5, 115.3, 112.4.
	Thiophene-2-carboxamide 2k: ¹ White solid, (61 mg, 71%); Mp: 182–183 °C; ^1H NMR (400 MHz, DMSO): δ 7.97 (s, 1H), 7.75 – 7.73 (m, 2H), 7.38 (s, 1H), 7.14 – 7.12 (m, 1H). ^{13}C NMR (101 MHz, DMSO): δ 163.4, 140.8, 131.4, 129.1, 128.4.
	Nicotinamide 2l: ¹ white solid, (66 mg, 76%); Mp: 130–131 °C; ^1H NMR (400 MHz, DMSO): δ 8.72 (s, 1H), 8.39 – 8.38 (m, 1H), 7.91 (s, 1H), 7.89 (s, 1H), 7.31 (s, 1H), 7.20 (J = 6.0 Hz, 1H). ^{13}C NMR (101 MHz, DMSO): δ 167.2, 152.4,




	149.0, 135.7, 130.1, 124.0.
	<p>2-(4-chlorophenoxy)-2-methylpropanamide 2p: white solid, (50 mg, 55%); Mp: 128–129 °C;</p> <p>¹H NMR (400 MHz, CDCl₃): δ 7.23 (d, <i>J</i> = 8.9 Hz, 2H), 6.88 (d, <i>J</i> = 8.9 Hz, 2H), 6.62 (s, 1H), 6.04 (s, 1H), 1.50 (s, 3H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 177.5, 152.8, 129.3, 129.0, 122.6, 81.7, 24.9.</p> <p>HRMS for C₁₀H₁₂ClNO₂ [M+H] Calculated: 214.0634 Found: 214.0652.</p>
	<p>2-(6-methoxynaphthalen-2-yl)propenamide 2q: white solid, (55 mg, 60%); Mp: 169–170 °C;</p> <p>¹H NMR (400 MHz, CDCl₃): δ 7.71–7.68 (m, 3H), 7.39 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.16 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 7.12 (d, <i>J</i> = 2.3 Hz, 1H), 5.43 (s, 1H), 5.36 (s, 1H), 3.92 (s, 3H), 3.74 (q, <i>J</i> = 7.2 Hz, 1H), 1.60 (d, <i>J</i> = 7.2 Hz, 3H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 176.8, 157.9, 136.3, 133.8, 129.2, 129.0, 127.7, 126.2, 126.1, 119.3, 105.7, 55.4, 46.6, 18.3.</p> <p>HRMS for C₁₄H₁₅NO₂ [M-H] Calculated: 228.1024 Found: 228.1010</p>
	<p>2-(3-benzoylphenyl)propenamide 2r: white solid, (41 mg, 45%); Mp: 139–140 °C;</p> <p>¹H NMR (400 MHz, CDCl₃): δ 7.80 (s, 3H), 7.68–7.60 (m, 3H), 7.51–7.46 (m, 3H), 6.05 (s, 1H), 5.78 (s, 1H), 3.71 (d, <i>J</i> = 5.7 Hz, 1H), 1.56 (d, <i>J</i> = 6.1 Hz, 3H)</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 196.6, 176.4, 141.8, 138.0, 137.4, 132.7, 132.0, 130.1, 129.2, 129.1, 128.8, 128.4, 46.4, 18.5.</p> <p>HRMS for C₁₆H₁₅NO₂ [M+H] Calculated: 254.1180 Found: 254.1168</p>




	<p>N-benzoylbenzamide 3a:² white solid, (50 mg, 63%); Mp: 150–152 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.84 (s, 1H), 7.81 (d, J = 7.1 Hz, 4H), 7.55 (t, J = 7.4 Hz, 2H), 7.45 (t, J = 7.6 Hz, 4H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 166.3, 133.4, 133.2, 128.9, 127.9.</p>
	<p>4-methyl-N-(4-methylbenzoyl)benzamide 3b:² white solid, (48 mg, 59%); Mp: 149–150 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.76 (s, 1H), 7.70 (d, J = 8.2 Hz, 4H), 7.24 (d, J = 8.0 Hz, 4H), 2.37 (s, 6H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 169.5, 142.6, 130.5, 129.3, 127.4, 21.5.</p>
	<p>4-methoxy-N-(4-methoxybenzoyl)benzamide 3c:² white solid, (47 mg, 57%); Mp: 154–156 °C; ¹H NMR (400 MHz, DMSO): δ 12.64 (s, 1H), 7.90 (d, J = 8.8 Hz, 4H), 7.02 (d, J = 8.8 Hz, 4H), 3.82 (s, 6H).</p> <p>¹³C NMR (101 MHz, DMSO): δ 167.5, 163.3, 131.8, 123.4, 114.3, 55.9.</p>
	<p>4-fluoro-N-(4-fluorobenzoyl)benzamide 3d:² white solid, (53 mg, 65%); Mp: 142–144 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.67 (s, 1H), 7.82 (dd, J = 8.6, 5.2 Hz, 4H), 7.12 (t, J = 8.5 Hz, 4H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 165.7, 130.8, 130.7, 129.3, 116.2, 116.0.</p> <p>¹⁹F NMR (377 MHz, CDCl₃): δ -104.51 – - 104.58 (m).</p>





	<p>3-methoxy-N-(3-methoxybenzoyl)benzamide 3f:² white solid, (43 mg, 52%); Mp: 123–125 °C; ¹H NMR (400 MHz, DMSO): δ 13.00 (s, 1H), 7.54 (d, J = 7.5 Hz, 2H), 7.44 – 7.39 (m, 4H), 7.19 (d, J = 8.0 Hz, 2H), 3.81 (s, 6H). ¹³C NMR (101 MHz, DMSO): δ 167.6, 159.7, 132.6, 130.2, 122.0, 119.4, 114.3, 55.7.</p>
	<p>3-fluoro-N-(3-fluorobenzoyl)benzamide 3g:² White solid, (49 mg, 60%); Mp: 135–136 °C; ¹H NMR (400 MHz, DMSO): δ 11.45 (s, 1H), 7.76 (d, J = 8.6 Hz, 4H), 7.59 (d, J = 6.9 Hz, 2H), 7.50 (t, J = 8.5 Hz, 2H). ¹³C NMR (101 MHz, DMSO): δ 166.8, 136.5, 131.1, 131.0, 125.3, 120.1, 119.9, 116.0, 115.8. ¹⁹F NMR (377 MHz, CDCl₃): δ -110.62 (d, J = 6.9 Hz).</p>
	<p>N-(1-naphthoyl)-1-naphthamide 3h:² white solid, (43 mg, 51%); Mp: 200–201 °C; ¹H NMR (400 MHz, DMSO): δ 11.90 (s, 1H), 8.23 (d, J = 7.7 Hz, 2H), 8.10 (d, J = 7.6 Hz, 2H), 8.03 (d, J = 7.2 Hz, 2H), 7.91 (d, J = 6.5 Hz, 2H), 7.64 – 7.58 (m, 6H). ¹³C NMR (101 MHz, DMSO): δ 169.4, 133.6,</p>

	133.2, 131.6, 130.1, 128.9, 127.8, 127.2, 126.9, 125.3, 125.2.
	<p>N-(2-naphthoyl)-2-naphthamide 3i:² white solid, (47 mg, 55%); Mp: 193–195 °C;</p> <p>¹H NMR (400 MHz, CDCl₃): δ 9.10 (s, 1H), 8.37 (s, 2H), 7.92 (dd, <i>J</i> = 8.2, 3.9 Hz, 4H), 7.88 – 7.84 (m, 4H), 7.59 – 7.51 (m, 4H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 166.6, 135.5, 132.5, 129.3, 129.1, 128.9, 128.7, 127.9, 127.2, 123.9.</p>
	<p>N-(furan-2-carbonyl)furan-2-carboxamide 3j:² White solid, (32 mg, 41%); Mp: 145–146 °C;</p> <p>¹H NMR (400 MHz, CDCl₃): δ 9.53 (s, 1H), 7.52 (s, 2H), 7.33 (s, 2H), 6.56 (s, 2H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 154.5, 146.6, 145.3, 118.1, 113.3.</p>
	<p>N-(thiophene-2-carbonyl)thiophene-2-carboxamide 3k:² White solid, (33 mg, 40%); Mp: 185–186 °C;</p> <p>¹H NMR (400 MHz, CDCl₃): δ 8.65 (s, 1H), 7.72 (d, <i>J</i> = 3.7 Hz, 2H), 7.61 (d, <i>J</i> = 4.9 Hz, 2H), 7.10 (t, <i>J</i> = 4.3 Hz, 2H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 159.5, 137.3, 133.5, 131.5, 128.1.</p>
	<p>2-(4-chlorophenoxy)-N-(2-(4-chlorophenoxy)-2-methylpropanoyl)-2-methylpropanamide 3l: White solid, (39 mg, 45%); Mp: 125–126 °C;</p> <p>¹H NMR (400 MHz, CDCl₃): δ 10.37 (s, 1H), 7.17 (d, <i>J</i> = 8.9 Hz, 4H), 6.68 (d, <i>J</i> = 8.9 Hz, 4H), 1.50 (s, 12H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 172.7, 152.2, 129.5, 129.0, 121.7, 82.1, 24.5.</p> <p>HRMS for C₂₀H₂₁Cl₂NO₄ [M+H] Calculated: 410.0925 Found: 410.0923</p>

	<p>2-(6-methoxynaphthalen-2-yl)-N-(2-(6-methoxynaphthalen-2-yl)propanoyl)propenamide 3m: White solid, (40 mg, 46%); Mp: 159–160 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.75 (t, <i>J</i> = 9.7 Hz, 6H), 7.39 (dd, <i>J</i> = 8.4, 1.8 Hz, 2H), 7.19 (dd, <i>J</i> = 8.9, 2.5 Hz, 2H), 7.14 (d, <i>J</i> = 2.3 Hz, 2H), 4.03 (q, <i>J</i> = 7.2 Hz, 2H), 3.93 (s, 6H), 1.71 (d, <i>J</i> = 7.3 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 174.0, 157.8, 134.8, 133.7, 129.2, 128.8, 127.5, 126.1, 126.1, 119.1, 105.5, 56.3, 47.1, 18.30. HRMS for C₂₈H₂₇NO₄ [M+H] Calculated: 442.2018 Found: 442.2040</p>
	<p>2-(3-benzoylphenyl)-N-(2-(3-benzoylphenyl)propanoyl)propenamide 3n: White solid, (32 mg, 36%); Mp: 132–134 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.08 (s, 1H), 7.75 (d, <i>J</i> = 7.5 Hz, 4H), 7.65 (d, <i>J</i> = 10.0 Hz, 4H), 7.60 (t, <i>J</i> = 7.3 Hz, 2H), 7.47 (t, <i>J</i> = 7.6 Hz, 4H), 7.38 – 7.31 (m, 4H), 4.27 (d, <i>J</i> = 6.8 Hz, 2H), 1.49 (d, <i>J</i> = 7.0 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 196.1, 173.8, 140.1, 138.0, 137.3, 133.0, 131.5, 130.1, 129.4, 129.3, 128.8, 128.3, 47.0, 18.6. HRMS for C₃₂H₂₇NO₄ [M+H] Calculated: 490.2018 Found: 490.2025</p>
	<p>N-benzoyl-4-methylbenzamide 4a:² Yellow solid, (147 mg, 87%); Mp: 106–107 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.93 (s, 1H), 7.79 (d, <i>J</i> = 7.1 Hz, 2H), 7.70 (d, <i>J</i> = 7.1 Hz, 2H), 7.53 (t, <i>J</i> = 6.7 Hz, 1H), 7.42 (t, <i>J</i> = 7.0 Hz, 2H), 7.22 (d, <i>J</i> = 7.1 Hz, 2H), 2.36 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.6, 166.3, 144.0, 133.5, 133.0, 130.5, 129.6, 128.9, 128.1, 128.0, 21.7.</p>

	<p>N-benzoyl-4-methoxybenzamide 4b:² White solid, (132 mg, 88%); Mp: 168–169 °C; ¹H NMR (400 MHz, DMSO) δ 11.17 (s, 1H), 7.93 (d, <i>J</i> = 7.8 Hz, 2H), 7.89 (d, <i>J</i> = 7.3 Hz, 2H), 7.63 (t, <i>J</i> = 6.9 Hz, 1H), 7.52 (t, <i>J</i> = 7.1 Hz, 2H), 7.06 (d, <i>J</i> = 7.8 Hz, 2H), 3.85 (s, 3H).</p> <p>¹³C NMR (101 MHz, DMSO): δ 168.4, 167.2, 163.3, 134.5, 132.9, 131.4, 129.0, 128.8, 126.2, 114.1, 56.0.</p>
	<p>N-benzoyl-4-fluorobenzamide 4c:² White solid, (144 mg, 94%); Mp: 128–129 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.92 (s, 1H), 7.83 – 7.78 (m, 4H), 7.54 (t, <i>J</i> = 7.2 Hz, 1H), 7.43 (t, <i>J</i> = 7.4 Hz, 2H), 7.10 (t, <i>J</i> = 8.1 Hz, 2H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 166.9, 166.5, 166.0, 164.4, 133.2, 133.2, 130.9, 130.8, 129.5, 129.5, 128.9, 128.0, 116.1, 115.9.</p> <p>¹⁹F NMR (377 MHz, CDCl₃): δ -104.85 (d, <i>J</i> = 6.5 Hz).</p>
	<p>N-benzoyl-4-chlorobenzamide 4d:² White solid, (141 mg, 95%); Mp: 126–127 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.04 (s, 1H), 7.78 (d, <i>J</i> = 7.3 Hz, 2H), 7.72 (d, <i>J</i> = 7.9 Hz, 2H), 7.52 (d, <i>J</i> = 7.1 Hz, 1H), 7.43 (d, <i>J</i> = 7.2 Hz, 2H), 7.38 (d, <i>J</i> = 9.1 Hz, 2H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 166.5, 166.2, 139.5, 133.3, 133.1, 131.7, 129.6, 129.1, 128.9, 128.0.</p>

	<p>N-benzoyl-3-methylbenzamide 4e:² White Solid, (125 mg, 81%); Mp: 95–97 °C; ¹H NMR (400 MHz, DMSO): δ 11.28 (s, 1H), 7.91 (d, J = 7.3 Hz, 2H), 7.75 (s, 1H), 7.72 (d, J = 7.1 Hz, 1H), 7.64 (t, J = 6.8 Hz, 1H), 7.53 (t, J = 7.0 Hz, 2H), 7.47 – 7.39 (m, 2H), 2.39 (s, 3H).</p> <p>¹³C NMR (101 MHz, DMSO): δ 168.2, 168.1, 138.2, 134.4, 134.2, 133.7, 133.0, 129.5, 129.1, 128.8, 128.8, 126.3, 21.3.</p>
	<p>N-benzoyl-3-methoxybenzamide 4f:² White Solid, (123 mg, 82%); Mp: 166–167 °C; ¹H NMR (400 MHz, DMSO): δ 11.30 (s, 1H), 7.90 (d, J = 7.3 Hz, 2H), 7.64 (t, J = 7.1 Hz, 1H), 7.55 – 7.50 (m, 3H), 7.46 – 7.42 (m, 2H), 7.21 (d, J = 7.8 Hz, 1H), 3.83 (s, 3H).</p> <p>¹³C NMR (101 MHz, DMSO): δ 168.3, 167.7, 159.6, 135.6, 134.4, 133.1, 130.1, 129.1, 128.8, 121.3, 119.1, 114.0, 55.9.</p>
	<p>N-benzoyl-2-methylbenzamide 4g:² White solid, (124 mg, 80%); Mp: 152–153 °C; ¹H NMR (400 MHz, DMSO): δ 11.45 (s, 1H), 7.92 (d, J = 7.4 Hz, 2H), 7.64 (t, J = 6.9 Hz, 1H), 7.54 – 7.46 (m, 3H), 7.40 (t, J = 7.3 Hz, 1H), 7.31 – 7.27 (m, 2H), 2.38 (s, 3H).</p> <p>¹³C NMR (101 MHz, DMSO): δ 170.7, 167.2, 136.4, 135.9, 133.7, 133.3, 131.0, 130.6, 129.1, 128.9, 128.0, 126.0, 19.8.</p>
	<p>N-benzoyl-1-naphthamide 4h:² White Solid,</p>


	<p>(122 mg, 85%); Mp: 128–129 °C; ¹H NMR (400 MHz, DMSO): δ 11.68 (s, 1H), 8.17 (d, J = 6.8 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 6.5 Hz, 1H), 7.95 (d, J = 7.3 Hz, 2H), 7.81 (d, J = 6.8 Hz, 1H), 7.64 – 7.58 (m, 4H), 7.52 (t, J = 7.1 Hz, 2H).</p> <p>¹³C NMR (101 MHz, DMSO): δ 170.2, 167.3, 133.9, 133.7, 133.6, 133.3, 131.3, 130.0, 129.1, 128.9, 127.7, 126.8, 126.7, 125.4, 125.1.</p>
	<p>N-benzoyl-2-naphthamide 4i:² White solid, (119 mg, 83%); Mp: 147–148 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.09 (s, 1H), 8.31 (s, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.83 (d, J = 7.5 Hz, 4H), 7.56 – 7.49 (m, 3H), 7.44 (t, J = 6.7 Hz, 2H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 166.6, 166.6, 135.5, 133.4, 133.1, 132.4, 130.5, 129.3, 129.1, 128.9, 128.9, 128.6, 128.1, 127.9, 127.2, 123.9.</p>
	<p>N-benzoylthiophene-2-carboxamide 4j:² White solid, (130 mg, 82%); Mp: 118–119 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.93 (s, 1H), 7.77 (d, J = 7.3 Hz, 2H), 7.73 (s, 1H), 7.59 (s, 1H), 7.52 (t, J = 7.1 Hz, 1H), 7.42 (t, J = 7.3 Hz, 2H), 7.09 (d, J = 3.2 Hz, 1H).</p> <p>¹³C NMR (101 MHz, CDCl₃): δ 166.4, 159.9, 137.5, 133.5, 133.4, 133.1, 131.3, 128.8, 128.2, 128.0.</p>
	<p>N-benzoylfuran-2-carboxamide 4k:² White Solid, (137 mg, 83%); Mp: 102–104 °C ¹H NMR (400 MHz, DMSO): δ 11.12 (s, 1H), 8.01 (s, 1H), 7.87 (d, J = 6.9 Hz, 2H), 7.64 (d, J = 6.8 Hz, 1H), 7.60 (s, 1H), 7.54 (t, J = 6.6 Hz, 2H), 6.74 (s, 1H).</p> <p>¹³C NMR (101 MHz, DMSO): δ 167.7, 157.2, 148.0, 146.8, 134.3, 133.1, 129.0, 128.9, 118.2, 112.8.</p>

4. References:

- (1) Y. Guo, R. Wang, J. Kang, Y. Ma, C. Xu, J. Li and X. Chen, Efficient synthesis of primary and secondary amides *via* reacting esters with alkali metal amidoboranes, *Nat. Commun.* 2021, **12**, 1-9.
- (2) J. Li, J. Yao, L. Chen, D. Zou, P. J. Walsh and G. Liang, Chemosselective acylation of *N*-acylglutarimides with *N*-acylpiperidines and aryl esters under transition-metal-free conditions. *Org. Chem. Front.* 2021, **8**, 6344-6349.


5. ^1H & ^{13}C NMR Spectra

Signature SIF VIT VELLORE
BENZ-AMIDE



BRUKER

^1H NMR
BENZ-AMIDE



Signature SIF VIT VELLORE
BENZ-AMIDE


— 169.8

— 133.4
— 132.0
— 128.6
— 127.4

— 77.4
— 77.1
— 76.7

BRUKER

^{13}C NMR
BENZ-AMIDE



Supplementary Figure 1. ^1H NMR and ^{13}C NMR spectrum of benzamide **2a**



Signature SIF VIT VELLORE
4-ME-AMIDE

7.652
7.632
7.193
7.167
7.167
6.020
5.892

2.834

BRUKER

CDCl₃
TMS



Signature SIF VIT VELLORE
4-ME-AMIDE


169.5
142.6
130.5
128.3
127.4

77.4
77.0
76.7

21.5



BRUKER

CDCl₃
TMS




Supplementary Figure 2. ¹H NMR and ¹³C NMR spectrum of 4-methylbenzamide **2b**


Signature SIF VIT VELLORE
4-MEO--AMIDE



Signature SIF VIT VELLORE
4-MEO--AMIDE




Supplementary Figure 3. ^1H NMR and ^{13}C NMR spectrum of 4-methoxybenzamide **2c**




Supplementary Figure 4. ^1H NMR and ^{13}C NMR spectrum of 4-fluorobenzamide **2d**

Signature SIF VIT VELLORE
4-F-AMIDE




Supplementary Figure 5. ¹⁹F NMR spectrum of 4-fluorobenzamide **2d**

Signature SIF VIT VELLORE
4CL-AMIDE




Supplementary Figure 6. ^1H NMR and ^{13}C NMR spectrum of 4-chlorobenzamide **2e**

Signature SIF VIT VELLORE
3-MEO-AMIDE



BRUKER




Supplementary Figure 7. ¹H NMR and ¹³C NMR spectrum of 3-methoxybenzamide **2f**

Signature SIF VIT VELLORE
3F-AMIDE




BRUKER



Signature SIF VIT VELLORE
3F-AMIDE




BRUKER




Supplementary Figure 8. ¹H NMR and ¹³C NMR spectrum of 3-fluorobenzamide **2g**

Signature SIF VIT VELLORE
3F-AMIDE




Supplementary Figure 9. ¹⁹F NMR spectrum of 3-fluorobenzamide **2g**




Supplementary Figure 10. ^1H NMR and ^{13}C NMR spectrum of 1-naphthamide **2h**

Signature SIF VIT VELLORE
2-Naph-AMIDE




Supplementary Figure 11. ¹H NMR and ¹³C NMR spectrum of 2-naphthamide 2i

Signature SIF VIT VELLORE
FURUYL-AMIDE





7.407
7.196
7.102
6.455
6.229
5.784

BRUKER




Supplementary Figure 12. ^1H NMR and ^{13}C NMR spectrum of furan-2-carboxamide **2j**

Signature SIF VIT VELLORE
THIO-AMIDE




Signature SIF VIT VELLORE
THIO-AMIDE




Supplementary Figure 13. ¹H NMR and ¹³C NMR spectrum of thiophene-2-carboxamide **2k**

Signature SIF VIT VELLORE
NICOTINAMIDE




Supplementary Figure 14. ¹H NMR and ¹³C NMR spectrum of nicotinamide **2l**


DM-CT-BS-SD4-1H



DM-CT-BS-SD4-13C





Supplementary Figure 15. ¹H NMR and ¹³C NMR spectrum of 2-(4-chlorophenoxy)-2-methylpropanamide 2p



Supplementary Figure 16. ^1H NMR and ^{13}C NMR spectrum of 2-(6-methoxynaphthalen-2-yl)propenamide **2q**

DM-BS-SD-6-1H




DM-BS-SD-6-13C

— 196.63
— 176.35

— 141.78
— 138.04
— 137.36
— 132.65
— 131.55
— 130.08
— 129.22
— 128.12
— 128.78
— 128.38


— 46.40
— 29.71
— 18.51

BRUKER




Supplementary Figure 17. ¹H NMR and ¹³C NMR spectrum of 2-(3-benzoylphenyl)propenamide **2r**

Signature SIF VIT VELLORE
BENZ-IMIDE




Supplementary Figure 18. ^1H NMR and ^{13}C NMR spectrum of *N*-benzoylbenzamide **3a**

Signature SIF VIT VELLORE
4-ME-IMIDE




Signature SIF VIT VELLORE
4-ME-IMIDE




Supplementary Figure 19. ¹H NMR and ¹³C NMR spectrum of 4-methyl-N-(4-methylbenzoyl)benzamide 3b

Signature SIF VIT VELLORE
4-OME-IMIDE




Signature SIF VIT VELLORE
4-OME-IMIDE




Supplementary Figure 20. ¹H NMR and ¹³C NMR spectrum of 4-methoxy-N-(4-methoxybenzoyl)benzamide 3c

Signature SIF VIT VELLORE
4-F-IMIDE




Supplementary Figure 21. ¹H NMR and ¹³C NMR spectrum of 4-fluoro-N-(4-fluorobenzoyl)benzamide 3d

Signature SIF VIT VELLORE
4-F-IMIDE




Supplementary Figure 22. ^{19}F NMR spectrum of 4-fluoro-*N*-(4-fluorobenzoyl)benzamide **3d**

Signature SIF VIT VELLORE
4CL-IMIDE




Supplementary Figure 23. ^1H NMR and ^{13}C NMR spectrum of 4-chloro-N-(4-chlorobenzoyl)benzamide 3e

Signature SIF VIT VELLORE
3MEO-IMDE




Supplementary Figure 24. ¹H NMR and ¹³C NMR spectrum of 3-methoxy-N-(3-methoxybenzoyl)benzamide 3f

Signature SIF VIT VELLORE
3F-IMIDE




Supplementary Figure 25. ^1H NMR and ^{13}C NMR spectrum of 3-fluoro-N-(3-fluorobenzoyl)benzamide 3g

Signature SIF VIT VELLORE
3F-IMIDE




Supplementary Figure 26. ¹⁹F NMR spectrum of 3-fluoro-N-(3-fluorobenzoyl)benzamide **3g**


Signature SIF VIT VELLORE
1-NAPH-IMIDE




Supplementary Figure 27. ¹H NMR and ¹³C NMR spectrum of *N*-(1-naphthoyl)-1-naphthamide **3h**




Supplementary Figure 28. ^1H NMR and ^{13}C NMR spectrum of *N*-(2-naphthoyl)-2-naphthamide **3i**



Supplementary Figure 29. ^1H NMR and ^{13}C NMR spectrum of *N*-(furan-2-carbonyl)furan-2-carboxamide **3j**





Supplementary Figure 30. ^1H NMR and ^{13}C NMR spectrum of *N*-(thiophene-2-carbonyl)thiophene-2-carboxamide **3k**




Supplementary Figure 31. ^1H NMR and ^{13}C NMR spectrum of 2-(4-chlorophenoxy)-N-(2-(4-chlorophenoxy)-2-methylpropanoyl)-2-methylpropanamide **3I**

DM-CT-SDR-2-1H


DM-CT-SD-R3-1³C

Supplementary Figure 32. ¹H NMR and ¹³C NMR spectrum of 2-(6-methoxynaphthalen-2-yl)-N-(2-(6-methoxynaphthalen-2-yl)propanoyl)propenamide **3m**


DM-BS-SD-7-1H



DM-BS-SD-7-1 3C




Supplementary Figure 33. ¹H NMR and ¹³C NMR spectrum of 2-(3-benzoylphenyl)-N-(2-(3-benzoylphenyl)propanoyl)propenamide **3n**




Supplementary Figure 34. ^1H NMR and ^{13}C NMR spectrum of *N*-benzoyl-4-methylbenzamide **4a**

Signature SIF VIT VELLORE
4MEO-CROSS





Supplementary Figure 35. ^1H NMR and ^{13}C NMR spectrum of *N*-benzoyl-4-methoxybenzamide **4b**

Signature SIF VIT VELLORE
4F-CROSS




Supplementary Figure 36. ¹H NMR and ¹³C NMR spectrum of *N*-benzoyl-4-fluorobenzamide **4c**


Signature SIF VIT VELLORE
4F-CROSS



Supplementary Figure 37. ^{19}F NMR spectrum of *N*-benzoyl-4-fluorobenzamide **4c**




Supplementary Figure 38. ^1H NMR and ^{13}C NMR spectrum of *N*-benzoyl-4-chlorobenzamide **4d**




Supplementary Figure 39. ¹H NMR and ¹³C NMR spectrum of *N*-benzoyl-3-methylbenzamide **4e**

Signature SIF VIT VELLORE
3-MCO-CROSS




Supplementary Figure 40. ^1H NMR and ^{13}C NMR spectrum of *N*-benzoyl-3-methoxybenzamide **4f**

Signature SIF VIT VELLORE
O-TOIL -CROY




Supplementary Figure 41. ¹H NMR and ¹³C NMR spectrum of *N*-benzoyl-2-methylbenzamide **4g**


Signature SIF VIT VELLORE
1-NAPH-CROYS



Supplementary Figure 42. ^1H NMR and ^{13}C NMR spectrum of *N*-benzoyl-1-naphthamide **4h**




Supplementary Figure 43. ¹H NMR and ¹³C NMR spectrum of *N*-benzoyl-2-naphthamide **4i**



Supplementary Figure 44. ¹H NMR and ¹³C NMR spectrum of *N*-benzoylthiophene-2-carboxamide **4j**

Signature SIF VIT VELLORE
FUTHYL-CROSS



Supplementary Figure 45. ¹H NMR and ¹³C NMR spectrum of *N*-benzoylfuran-2-carboxamide **4k**